BACKGROUND: Recent data showed that melanoma was more common among patients with Parkinson disease than individuals without Parkinson disease and vice versa. It has been hypothesized that these two diseases may share common genetic and environmental risk factors. METHODS: We evaluated the association between single-nucleotide polymorphisms (SNP) selected on the basis of recent genome-wide association studies (GWAS) on Parkinson disease risk and the risk of melanoma using 2,297 melanoma cases and 6,651 controls. RESULTS: The Parkinson disease SNP rs156429 in the chromosome 7p15 region was nominally associated with melanoma risk with P value of 0.04, which was not significant after the Bonferroni correction for multiple comparisons. No association was observed between the remaining 31 Parkinson disease SNPs and the risk of melanoma. The genetic score based on the number of Parkinson disease risk allele was not associated with melanoma risk [OR for the highest genetic score quartile (30-35) vs. the lowest (15-20), 1.13, 95% confidence interval (CI), 0.47-2.70]. CONCLUSION: The Parkinson disease SNPs identified in published GWAS do not seem to play an important role in melanoma development. IMPACT: The Parkinson disease susceptibility loci discovered by GWAS contribute little to the observed epidemiologic association between the Parkinson disease and melanoma.
BACKGROUND: Recent data showed that melanoma was more common among patients with Parkinson disease than individuals without Parkinson disease and vice versa. It has been hypothesized that these two diseases may share common genetic and environmental risk factors. METHODS: We evaluated the association between single-nucleotide polymorphisms (SNP) selected on the basis of recent genome-wide association studies (GWAS) on Parkinson disease risk and the risk ofmelanoma using 2,297 melanoma cases and 6,651 controls. RESULTS: The Parkinson disease SNP rs156429 in the chromosome 7p15 region was nominally associated with melanoma risk with P value of 0.04, which was not significant after the Bonferroni correction for multiple comparisons. No association was observed between the remaining 31 Parkinson disease SNPs and the risk ofmelanoma. The genetic score based on the number ofParkinson disease risk allele was not associated with melanoma risk [OR for the highest genetic score quartile (30-35) vs. the lowest (15-20), 1.13, 95% confidence interval (CI), 0.47-2.70]. CONCLUSION: The Parkinson disease SNPs identified in published GWAS do not seem to play an important role in melanoma development. IMPACT: The Parkinson disease susceptibility loci discovered by GWAS contribute little to the observed epidemiologic association between the Parkinson disease and melanoma.
Authors: D Michal Freedman; Alice Sigurdson; Michele Morin Doody; R Sowmya Rao; Martha S Linet Journal: Cancer Causes Control Date: 2003-11 Impact factor: 2.506
Authors: Jiali Han; Abrar A Qureshi; Jennifer Prescott; Qun Guo; Li Ye; David J Hunter; Immaculata De Vivo Journal: J Invest Dermatol Date: 2008-07-31 Impact factor: 8.551
Authors: Andreas Bender; Kim J Krishnan; Christopher M Morris; Geoffrey A Taylor; Amy K Reeve; Robert H Perry; Evelyn Jaros; Joshua S Hersheson; Joanne Betts; Thomas Klopstock; Robert W Taylor; Douglass M Turnbull Journal: Nat Genet Date: 2006-04-09 Impact factor: 38.330
Authors: Elisa Turriani; Diana F Lázaro; Sergey Ryazanov; Andrei Leonov; Armin Giese; Margarete Schön; Michael P Schön; Christian Griesinger; Tiago F Outeiro; Donna J Arndt-Jovin; Dorothea Becker Journal: Proc Natl Acad Sci U S A Date: 2017-06-05 Impact factor: 11.205
Authors: Heather M Snyder; Tim Ahles; Stuart Calderwood; Maria C Carrillo; Honglei Chen; Chung-Chou H Chang; Suzanne Craft; Philip De Jager; Jane A Driver; Howard Fillit; David Knopman; Michael Lotze; Mary C Tierney; Suzana Petanceska; Andrew Saykin; Sudha Seshadri; Diana Shineman; Mary Ganguli Journal: Alzheimers Dement Date: 2016-12-18 Impact factor: 21.566
Authors: Ziv Gan-Or; Noreen Mohsin; Simon L Girard; Jacques Y Montplaisir; Amirthagowri Ambalavanan; Stephanie Strong; Victoria Mallett; Sandra B Laurent; Cynthia V Bourassa; Michel Boivin; Melanie Langlois; Isabelle Arnulf; Birgit Högl; Birgit Frauscher; Christelle Monaca; Alex Desautels; Jean-François Gagnon; Ronald B Postuma; Patrick A Dion; Yves Dauvilliers; Nicolas Dupre; Roy N Alcalay; Guy A Rouleau Journal: Neurobiol Aging Date: 2016-04-06 Impact factor: 4.673
Authors: S J Lubbe; V Escott-Price; A Brice; T Gasser; A M Pittman; J Bras; J Hardy; P Heutink; N M Wood; A B Singleton; D G Grosset; C B Carroll; M H Law; F Demenais; M M Iles; D T Bishop; J Newton-Bishop; N M Williams; H R Morris Journal: Neurobiol Aging Date: 2016-07-28 Impact factor: 4.673
Authors: Joan Anton Puig-Butille; María José Escámez; Francisco Garcia-Garcia; Gemma Tell-Marti; Àngels Fabra; Lucía Martínez-Santamaría; Celia Badenas; Paula Aguilera; Marta Pevida; Joaquín Dopazo; Marcela del Río; Susana Puig Journal: Oncotarget Date: 2014-03-30